DexCom earnings beat by $0.03, revenue topped estimates
FREEHOLD, N.J. - Avalon GloboCare Corp. (NASDAQ:ALBT), a micro-cap biotechnology company with a market capitalization of $5.2 million, has been granted a new standard patent by the Hong Kong Intellectual Property Department for its CAR-T and CAR-Natural Killer cell technology, the company announced Monday. InvestingPro data shows the company has achieved impressive revenue growth of 111% over the last twelve months.
The patent, issued as No. HK40074322 and based on a Chinese patent, provides 20-year protection effective from February 21, 2020. The technology was co-developed with Hong Kong-based Arbele Limited.
According to the company, the patented technology features a bispecific design targeting both CD19 and CD22 antigens, which may reduce the risk of tumor escape in blood cancers. It also includes localized cytokine induction intended to activate immune responses at tumor sites.
"Securing this patent in Hong Kong marks an important expansion of our global intellectual property portfolio," said David Jin, CEO of Avalon GloboCare, in a statement released by the company.
The Hong Kong patent complements Avalon’s existing protections in the United States and other jurisdictions under the Patent Cooperation Treaty.
Avalon GloboCare, which describes itself as a developer of precision diagnostic consumer products, is currently marketing the KetoAir breathalyzer device, registered with the FDA as a Class I medical device. The company is also pursuing a proposed merger with YOOV Group Holding Limited, for which it has filed registration materials with the SEC.
The patent announcement comes as Avalon continues to develop its intellectual property portfolio while maintaining its commercial real estate operations. The company’s stock has faced significant challenges, declining 64.8% over the past year. InvestingPro subscribers have access to 12 additional key insights about ALBT, including detailed financial health metrics and growth indicators.
This article is based on a press release statement from Avalon GloboCare. According to InvestingPro analysis, the company currently maintains a weak financial health score of 0.91, with short-term obligations exceeding liquid assets. Investors can access comprehensive financial analysis and real-time updates through InvestingPro’s advanced analytics platform.
In other recent news, Avalon GloboCare Corp. has issued two convertible promissory notes totaling $200,000 to accredited investors. The notes, each with a principal amount of $100,000, carry a one-time interest charge of $30,000 and mature nine months from issuance. Investors can convert the notes into common stock at a fixed price of $1.00 per share, with certain limitations on ownership and share issuance. Additionally, Avalon GloboCare faces a potential delisting from Nasdaq due to failing to meet the minimum stockholders’ equity requirement of $2.5 million, with their equity reported at a deficit of ($3,891,270) as of March 31, 2025. The company has until July 7, 2025, to submit a compliance plan, with a possible extension to November 18, 2025. Avalon plans to submit a compliance plan but acknowledges the uncertainty of Nasdaq’s acceptance. The company also noted that their pending merger with YOOV Group Holding Limited is contingent upon meeting certain conditions, including maintaining their stock listing. These developments were detailed in recent filings with the Securities and Exchange Commission.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.